Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | NQO2 | P16083 | 1/20 | 0.48 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | ESRRB | O95718 | 1/20 | 0.38 |
| ▸ | ESRRA | P11474 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8407455 | 0.89 | TDP1 (0.49) | KMT2AMEN1NQO2ACHEGAA | |
| SCHEMBL8407324 | 0.89 | MEN1 (0.51) | KMT2AMEN1NQO2GAAL3MBTL1 | |
| SCHEMBL8407300 | 0.87 | MEN1 (0.69) | KMT2AMEN1GAAL3MBTL1KDM4E | |
| SCHEMBL28037618 | 0.85 | KMT2A (0.71) | KMT2AMEN1NQO2ACHEGAA | |
| SCHEMBL8407376 | 0.85 | KMT2A (0.71) | KMT2AMEN1NQO2ACHEGAA | |
| SCHEMBL19861862 | 0.80 | FGFR1 (0.50) | KMT2AMEN1NQO2ACHEGAA | |
| SCHEMBL30575027 | 0.78 | ACHE (0.63) | KMT2AMEN1NQO2ACHEGAA | |
| SCHEMBL8371593 | 0.78 | ACHE (0.63) | KMT2AMEN1NQO2ACHEGAA | |
| SCHEMBL8407229 | 0.77 | KMT2A (0.67) | KMT2AMEN1GAAL3MBTL1KDM4E | |
| SCHEMBL23474673 | 0.75 | KDM4E (0.69) | KMT2AMEN1GAAL3MBTL1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230210849-A1 | CADHERIN-11 INHIBITOR FORMULATION AND ITS USES IN IMMUNOTHERAPY | GEORGETOWN UNIVERSITY (US) | 2023-07-06 | — | — | US | disclosed |
| US-20230210849-A1 | CADHERIN-11 INHIBITOR FORMULATION AND ITS USES IN IMMUNOTHERAPY | GEORGETOWN UNIVERSITY (US) | 2023-07-06 | — | — | US | disclosed |
| US-9889131-B2 | Cadherin-11 inhibitors and methods of use thereof | GEORGETOWN UNIVERSITY (US) | 2018-02-13 | — | — | US | disclosed |
| US-9889131-B2 | Cadherin-11 inhibitors and methods of use thereof | GEORGETOWN UNIVERSITY (US) | 2018-02-13 | — | — | US | disclosed |
| EP-2393787-B1 | CADHERIN-11 INHIBITORS AND METHODS OF USE THEREOF | UNIV GEORGETOWN (US) | 2018-01-24 | — | — | EP | disclosed |
| US-20170360934-A1 | USE OF CADHERIN-11 ANTAGONISTS TO TREAT OBESITY-ASSOCIATED CONDITIONS AND OTHER METABOLIC DISORDERS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2017-12-21 | — | — | US | disclosed |
| US-20170360934-A1 | USE OF CADHERIN-11 ANTAGONISTS TO TREAT OBESITY-ASSOCIATED CONDITIONS AND OTHER METABOLIC DISORDERS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2017-12-21 | — | — | US | disclosed |
| US-20160151363-A1 | Cadherin-11 Inhibitors and Methods of Use Thereof | GEORGETOWN UNIVERSITY (US) | 2016-06-02 | — | — | US | disclosed |
| US-20160151363-A1 | Cadherin-11 Inhibitors and Methods of Use Thereof | GEORGETOWN UNIVERSITY (US) | 2016-06-02 | — | — | US | disclosed |
| US-9284368-B2 | Substituted pyrazines as cadherin-11 inhibitors | GEORGETOWN UNIVERSITY (US) | 2016-03-15 | — | — | US | disclosed |
| US-20150064168-A1 | Cadherin-11 Inhibitors and Methods of Use Thereof | UNITED STATES GOVERNMENT | 2015-03-05 | — | — | US | disclosed |
| US-20150064168-A1 | Cadherin-11 Inhibitors and Methods of Use Thereof | UNITED STATES GOVERNMENT | 2015-03-05 | — | — | US | disclosed |
| US-8802687-B2 | Cadherin-11 inhibitors and methods of use thereof | GEORGETOWN UNIVERSITY (US) | 2014-08-12 | — | — | US | disclosed |
| US-8802687-B2 | Cadherin-11 inhibitors and methods of use thereof | GEORGETOWN UNIVERSITY (US) | 2014-08-12 | — | — | US | disclosed |
| US-20120128693-A1 | CADHERIN-11 INHIBITORS AND METHODS OF USE THEREOF | GEORGETOWN UNIVERSITY (US) | 2012-05-24 | — | — | US | disclosed |
| US-20120128693-A1 | CADHERIN-11 INHIBITORS AND METHODS OF USE THEREOF | GEORGETOWN UNIVERSITY (US) | 2012-05-24 | — | — | US | disclosed |
| WO-2010091384-A2 | CADHERIN-11 INHIBITORS AND METHODS OF USE THEREOF | GEORGETOWN UNIVERSITY (US) | 2010-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150064168-A1 | Cadherin-11 Inhibitors and Methods of Use Thereof | CDH1, ICAM1, S100A11 | KMT2A 2318/4885MEN1 1025/4885NQO2 739/4885 |
| US-20160151363-A1 | Cadherin-11 Inhibitors and Methods of Use Thereof | CDH1, ICAM1, S100A11 | KMT2A 2318/4885MEN1 1025/4885NQO2 739/4885 |
| US-20230210849-A1 | CADHERIN-11 INHIBITOR FORMULATION AND ITS USES IN IMMUNOTHERAPY | CDH1, DSC1, EPCAM | KMT2A 2020/4885MEN1 91/4885NQO2 4228/4885 |
| US-20170360934-A1 | USE OF CADHERIN-11 ANTAGONISTS TO TREAT OBESITY-ASSOCIATED CONDITIONS AND OTHER METABOLIC DISORDERS | CDH1, GPR119, FABP4 | KMT2A 2427/4885MEN1 1468/4885NQO2 2861/4885 |
| US-20120128693-A1 | CADHERIN-11 INHIBITORS AND METHODS OF USE THEREOF | CDH1, ICAM1, S100A11 | KMT2A 2318/4885MEN1 1025/4885NQO2 739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.